Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP:MDXXF)

0.1121 -0.0053 (-4.51%)
Streaming Delayed Price Updated: 11:36 AM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,000
Open 0.1121
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1174
Today's Range 0.1121 - 0.1121
52wk Range 0.0476 - 0.2563
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PharmAla Contracts with Partner to Act as US Distributor
From PharmAla Biotech
Via GlobeNewswire
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
From PharmAla Biotech
Via GlobeNewswire

Performance

YTD
-37.3%
-37.3%
1 Month
-0.4%
-0.4%
3 Month
-24.7%
-24.7%
6 Month
-13.1%
-13.1%
1 Year
-16.1%
-16.1%

More News

Read More
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
From PharmAla Biotech
Via GlobeNewswire
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
From PharmAla Biotech
Via GlobeNewswire
PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial
Via Benzinga
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
From PharmAla Biotech
Via GlobeNewswire
PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial
Via Benzinga
PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial
Via Benzinga
PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract
Via Benzinga
PharmAla Launches MDMA Clinical Trial Tool for Researchers
From PharmAla Biotech
Via GlobeNewswire
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
From PharmAla Biotech
Via GlobeNewswire
Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale
Via Benzinga
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
From PharmAla Biotech
Via GlobeNewswire
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
From PharmAla Biotech
Via GlobeNewswire
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
Via Benzinga
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
From PharmAla Biotech
Via GlobeNewswire
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
From PharmAla Biotech
Via GlobeNewswire
Truffles To Market: Red Light Holland Wants To Develop Psilocybin API At Scale
Via Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga

Frequently Asked Questions

Is MDXXF publicly traded?
Yes, MDXXF is publicly traded.
What exchange does MDXXF trade on?
MDXXF trades on the OTC Traded
What is the ticker symbol for MDXXF?
The ticker symbol for MDXXF is MDXXF on the OTC Traded
What is the current price of MDXXF?
The current price of MDXXF is 0.1121
When was MDXXF last traded?
The last trade of MDXXF was at 04/30/25 11:36 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.